Psoriasis Redefined Webinar Series

Orbit 360 enabled
Off

A series of two CPD certified modules, presented by recognised experts in clinical psoriasis to support you should you decide to use BIMZELX® ▼ (bimekizumab) for treating your eligible adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Orbit 360 enabled
Off
Orbit 360 enabled
Off
Off

The BIMZELX®  Difference

paragraph-section-webinars

Psoriasis Redefined webinar 1

The BIMZELX®  Difference
Learn & discover
Describe the importance of both IL-17F and IL-17A in the pathogenesis of psoriasis
Explain how dual-inhibition of IL-17F and IL-17A with BIMZELX® affects both IL-17 and IL-23 pro-inflammatory pathways in psoriasis
Recall key data on efficacy, durability and tolerability from the extensive BIMZELX® clinical trial programme in patients with plaque psoriasis
Recognise the BIMZELX® enhanced Patient Support Programme
View module
zoom button Click to enlarge
Presenters
  • Professor Richard Warren
  • Stevan Shaw (UCB)
  • Dr Kave Shams
  • Lucy Moorhead
Keep track of your progress
Login or Register to download your CPD certificate and Learning Guide
Duration
39:19 minutes
Date of preparation: February 2023 | IE-P-BK-PSO-2200032
On

The BIMZELX®  Experience

paragraph-section-webinars

Psoriasis Redefined webinar 2

The BIMZELX®  Experience
Learn & discover
Understand the unmet needs of patients with psoriasis
Identify which patient characteristics may benefit from BIMZELX® and why
View module
zoom button Click to enlarge
Presenters
  • Professor Richard Warren
  • Professor Anthony Bewley
  • Dr Amy Foulkes
Keep track of your progress
Login or Register to download your CPD certificate and Learning Guide
Duration
27:55 minutes
Date of preparation: February 2023 | IE-P-BK-PSO-2200032
On
Because we're in this together...

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Click here for Prescribing Information Great Britain Click here for Prescribing Information Northern Ireland and Republic of Ireland

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: February 2023
IE-P-BK-PSO-2200032